Japanese company profile · 4937
株式会社Waqoo
The original Japanese company name is shown; no English name has been verified.
FY2024 · fiscal year ended September 2025Latest filing date: 2025-12-23What does this company do?
What does this company do?
The latest available public filing reports Direct-to-Consumer (D2C) Business, Medical Support Business. The original Japanese company name is shown with the source information.
This company's largest reported business by revenue in FY2024 was Medical Support Business.
The business with the highest reported segment profit in FY2024 was Direct-to-Consumer (D2C) Business.
FY2024 · fiscal year ended September 2025 · View original filing ↗ The source document may be in Japanese.
Reported company-wide figures
- Company revenue
- ¥1.96B ↗ FY2024 · fiscal year ended September 2025
- Operating profit
- ¥150.94M ↗ FY2024 · fiscal year ended September 2025
- Comparable margin
- 7.7% ↗ FY2024 · fiscal year ended September 2025
JGAAP · Consolidated company-wide
Company profile
Identity
- Securities code
- 4937
- EDINET code
- E36697
- Corporate number
- 9010901023800
- Listing status
- Listed
- Industry (EDINET filer classification)
- Chemicals
Location and fiscal year
- Headquarters
- 東京都世田谷区 · As filed in Japanese
- Fiscal year end
- 9month
- Latest fiscal year
- FY2024
- Accounting standard
- JGAAP
- P16 data snapshot
- 2026-11-07
Company size
- Employees (consolidated)
- 93 people (FY2024)
- Employees (non-consolidated)
- 61 people (FY2024)
- Capital stock
- JPY 54.6 million (FY2024)
Official information
- Latest annual securities report
- Latest annual securities report Opens in a new tab
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
How does it make money?
Revenue leader and profit leader
RevenueMedical Support Business
ProfitDirect-to-Consumer (D2C) Business
| Business | Sales | Share of company sales | Operating profit | Margin |
|---|---|---|---|---|
| Medical Support Business | ¥1B ↗ | 50.9% | ¥216.1M ↗ | 21.6% |
| Direct-to-Consumer (D2C) Business | ¥952.59M ↗ | 48.6% | ¥294.8M ↗ | 30.9% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2024 · fiscal year ended September 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Company-wide trend
Company revenue
JGAAP · Consolidated- FY2021
100.0 ¥2.73B - FY2022
63.2 ¥1.73B - FY2023
71.2 ¥1.94B - FY2024
71.8 ¥1.96B
Company revenue
JGAAP · Parent-only- FY2020
100.0 ¥4.68B
Company operating profit
JGAAP · Consolidated- FY2021
14.3 −¥39.78M - FY2022
100.0 ¥277.94M - FY2023
20.2 ¥56.12M - FY2024
54.3 ¥150.94M
Company operating profit
JGAAP · Parent-only- FY2020
100.0 ¥149.3M
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
What has changed?
Businesses reported in earlier filings
Reporting labels alone do not prove that a business started, ended, merged, or changed its identity.
- Direct-to-Consumer (D2C) BusinessFY 2020 · Source
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Direct-to-Consumer (D2C) Business | ¥2.53B | ¥1.56B | ¥1.32B | ¥952.59M |
| Medical Support Business | ¥200.01M | ¥166.5M | ¥628.67M | ¥1B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
No comparable reported revenue growth is available.
What has changed?
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
Company profile
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
- GrowthPeer-position scoreFY2024
1 - ProfitabilityPeer-position scoreFY2024
55 - Business concentrationPeer-position scoreFY2024
20 - Business changePeer-position scoreFY2021→FY2024
99 - Cash generationPeer-position scoreFY2024
29 - Growth persistencePeer-position scoreFY2021→FY2022, FY2022→FY2023, FY2023→FY2024
29
Source
Public filing
FY2024 · fiscal year ended September 2025
The source document may be in Japanese.
Filing ID: S100XCAJ
View original filing ↗